NIVOLUMAB OPDYTA 100MG

Nivolumab OPDYTA 100mg Injection contains nivolumab, a prescription immunotherapy medicine classified as a PD-1 immune checkpoint inhibitor. It is widely used in the treatment of non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma, Hodgkin lymphoma, and several other advanced cancers. By activating the immune system, this targeted therapy helps the body recognize and attack cancer cells more effectively.

Nivolumab works by blocking the programmed death-1 (PD-1) pathway, which cancer cells use to evade immune detection. This mechanism enhances the body’s natural immune response, supporting durable tumor control and improved treatment outcomes across multiple cancer types when used as part of prescribed oncology protocols.

Administered as an intravenous infusion, Nivolumab OPDYTA 100 mg Injection is used in hospital and oncology clinic settings under the strict supervision of an oncologist. Its immunotherapy-based approach makes it a key component of modern cancer treatment strategies, ensuring controlled and targeted therapy for eligible patients.

Product Features

• Monoclonal PD-1 immune checkpoint inhibitor
• Contains Nivolumab 100 mg
• Used in NSCLC, melanoma, renal cell carcinoma, Hodgkin lymphoma
• Enhances anti-tumor immune response
• Administered via intravenous infusion
• Hospital / clinical oncology use
• Manufactured under GMP-compliant standards
• Prescription-required immunotherapy injection.

How It Helps

• Blocks the PD-1 pathway to enhance immune system activity
• Helps the body recognize and attack cancer cells
• Supports tumor control in NSCLC, melanoma, and other cancers
• Provides targeted immunotherapy under an oncologist’s supervision